N/A
Completed N=486
Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients
Source: ClinicalTrials.gov NCT04398732 ↗Enrolled (actual)
486
Serious AEs
—
Results posted
Nov 2021
Primary outcomePrimary: Change From Baseline in Percent Body Surface Area (BSA) at Month 12 — -21 Percent BSA — p=0.0001
Summary
This study is to evaluate available local data in Iraqi patients with moderate to severe psoriasis on Enbrel treatment with regards to efficacy, treatment regimen adherence and patient characterization (i.e. age, gender, smoking status) using data from the Dermatologists in Baghdad Teaching Hospital registry
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Percent Body Surface Area (BSA) at Month 12 |
-21 | 0.0001 sig |
| PRIMARY Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Month 12 |
-17.2 | 0.0001 sig |
| PRIMARY Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Month 12 |
-16.44 | 0.0001 sig |
| SECONDARY Percent Body Surface Area (BSA) at Baseline, Month 4, and Month 12 in Participants Adherent and Not Adherent to Treatment |
27.56; 32.84; 20.1; 31.7; 8.7; 11.1 | 0.036 sig |
| SECONDARY Dermatology Life Quality Index (DLQI) Score at Baseline, Month 4 and Month 12 in Participants Adherent and Not Adherent to Treatment |
24.50; 24.94; 16.6; 21.1; 6.6; 11.3 | 0.42 |
| SECONDARY Psoriasis Area and Severity Index (PASI) Score at Baseline, Month 4 and Month 12 in Participants Adherent and Not Adherent to Treatment |
21.980; 22.458; 14.5; 21.7; 4.8; 9.7 | 0.72 |
Eligibility Criteria
Inclusion Criteria
- Confirmed diagnosis of moderate to severe plaque psoriasis receiving etanercept treatment for a minimum duration of 1 year.
- Age ≥18 years old.
- No history of using a biological treatment, other than etanercept, for treatment of moderate to severe plaque psoriasis or any other reason.
Exclusion Criteria
- Etanercept use for treatment moderate to severe plaque psoriasis less than 1 year duration.
- Previous use of other biological treatments for any reason
Data sourced from ClinicalTrials.gov (NCT04398732). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.